Inactive Instrument

ARPIDA Share Price Swiss Exchange

ARPN

Biotechnology & Medical Research

End-of-day quote Swiss Exchange
- ^CHF	-

11-02	EvoNext Holdings Enters Deal to Merge with Ascend Sport Technology	MT
10-12	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT

Analysts' recommendations: ARPIDA

05/11/20

Evolva : Octavian Lowers Price Target on Evolva, Maintains Hold Recommendation

More recommendations

News in other languages: ARPIDA

11-02	EvoNext: fusion avec Ascend Sport Technology actée
11-02	Evonext und Ascend unterzeichnen Fusionsvertrag
10-12	Ascend Sport Technology sbarcherà in borsa
10-12	Sporttech-Firma Ascend will durch Fusion mit EvoNext an Schweizer Börse
10-12	Evonext und Ascend Sport einigen sich auf Fusion

More news

Managers and Directors: ARPIDA

Manager	Title	Age	Since
Doris Rudischhauser IRC	Investor Relations Contact	59	-

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	26/03/2025
Gianluca Ferrari CHM	Chairman	-	26/03/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+10.00%	+5.18%	+54.35%	+71.20%	60.57B
LONZA GROUP AG	+1.44%	+4.06%	+22.70%	+101.03%	55.51B
ARGENX SE	+3.32%	+4.11%	+14.82%	+75.04%	55.22B
IQVIA HOLDINGS INC.	+0.46%	-2.86%	+23.34%	+33.77%	43.27B
BEONE MEDICINES AG	+6.42%	+3.20%	+21.14%	+105.56%	40.36B
REVOLUTION MEDICINES, INC.	+2.82%	+7.24%	+236.59%	+801.17%	41.63B
GENMAB A/S	-3.79%	+19.39%	+91.90%	+77.13%	33.29B
CELLTRION, INC.	+5.32%	+6.04%	+20.27%	+52.98%	32.27B
INSMED INCORPORATED	+5.32%	+15.84%	-40.93%	+342.66%	22.91B
Average	+3.48%	+5.02%	+49.35%	+184.51%	42.78B
Weighted average by Cap.	+3.72%	+4.06%	+51.58%	+169.51%

See all sector performances

EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	16.88M 20.66M 18.39M 15.33M 28.86M 1.95B 29.49M 201M 80.66M 1.03B 77.53M 75.87M 3.27B	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	10.97M 13.43M 11.95M 9.96M 18.76M 1.27B 19.17M 131M 52.43M 672M 50.4M 49.32M 2.13B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	62.03%	Yield 2024 *	-	Yield 2025	-

11-02	EvoNext Holdings Enters Deal to Merge with Ascend Sport Technology	MT
10-12	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT
10-11	Ascend Sport Technology AG signed a binding transaction agreement to acquire EvoNext Holdings SA for approximately CHF 500 million in a reverse merger transaction.	CI
09-30	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-30	EvoNext Holdings' H1 Net Loss Widens; Financial Income Up	MT
08-18	Evonext Holds Talks to Take Ascend Sport Public	CI
08-18	EvoNext in Advanced Negotiations with Ascend Sport Technology for Reverse Merger	MT
08-17	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
08-17	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
04-30	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
20/08/25	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/07/25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25/07/25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI

11-02	EvoNext Holdings SA and Ascend Sport Technology AG sign merger agreement	EQ
10-12	EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement	EQ
09-30	EvoNext Holdings SA publishes half-year report 2026	EQ
08-17	EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG	EQ
05-20	EvoNext : Minutes of Annual General Meeting 2026	PU

	2024	2025
Net sales	-	-
Net income	1.04M 1.28M 1.14M 948K 1.79M 121M 1.82M 12.44M 4.99M 63.91M 4.8M 4.69M 202M	-653K -799K -711K -593K -1.12M -75.61M -1.14M -7.78M -3.12M -39.97M -3M -2.93M -127M
Net Debt	-6.75M -8.27M -7.36M -6.13M -11.55M -782M -11.8M -80.47M -32.28M -414M -31.03M -30.36M -1.31B	-5.91M -7.23M -6.44M -5.36M -10.1M -684M -10.32M -70.37M -28.23M -362M -27.13M -26.55M -1.15B

ARPIDA Share Price Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news: ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile